Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in Low Grade Lymphoma
NCT00003204Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 1998
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Time to treatment failure up to 5 years. Started Mar 1998; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003204.